TP53 hotspot R282W in CLL — DNA-binding domain dominant-negative variant. Same therapeuti...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-TP53-R282W-CLL |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-CLL |
| Sources | SRC-CIVIC SRC-ESMO-CLL-2024 SRC-NCCN-BCELL-2025 |
Actionability Facts
| Biomarker | BIO-TP53-MUTATION |
|---|---|
| Variant | R282W |
| Disease | DIS-CLL |
| ESCAT tier | IIIA |
| Recommended combinations | acalabrutinib, venetoclax + obinutuzumab |
| Evidence summary | TP53 hotspot R282W in CLL — DNA-binding domain dominant-negative variant. Same therapeutic implications as gene-level TP53-mut: BTKi or BCL2i, avoid chemoimmuno. |
Notes
ESCAT IIIA. R282W is among the most common TP53 hotspots in CLL.
Used By
No reverse references found in the YAML corpus.